In this piece, we will discuss the 10 Most Active Penny Stocks to Buy.
The 2026 Iran conflict has resulted in a spike in volatility across markets, with the conflict expected to persist amid escalating geopolitical tensions. The broader investor sentiment is showing risk aversion as markets have noted significant declines since the start of the armed conflict on February 28, 2026, Forbes reports on March 15, 2026. The S&P 500 fell by 3.5% and international equities declined 8.3% during this period.
Meanwhile, oil prices, which remain important for the overall market dynamics, continue to influence investor sentiment. From the pre-conflict level of $67 per barrel, WTI crude oil surged to nearly $100 per barrel on March 13, 2026. While this surge has driven a 3.2% rise in energy stocks, broader equities remain under pressure.
At the same time, inflation concerns and challenges in consumer-facing sectors continue to intensify amid rising gasoline prices, which have risen from $2.98 to $3.68 per gallon.
Amid this uncertain macroeconomic backdrop, Forbes notes that prediction markets now indicate a 34% chance of a 2026 recession, up from 22% before the start of the Iran conflict. On the positive side, it also reported a historical analysis of 29 geopolitical events, which suggests market recovery historically occurs within a month. This highlights that volatility can create selective opportunities even in uncertain periods.
With this background in mind, we will turn our focus to our list of the most active penny stocks. Increased trading activity in these stocks can indicate rising investor interest based on news flow or speculation. Indeed, these stocks carry higher risk, but they may offer good opportunities for investors who are looking to invest in high-activity segments despite volatility.
Methodology
To identify the 10 most active penny stocks to buy, we used a stock screener to filter stocks trading under $5 with an average trading volume above 2 million shares. These stocks were then sorted by volume to highlight the most actively traded.
Next, we ranked these stocks using Q4 2025 hedge fund data from Insider Monkey to identify the stocks with the highest institutional interest. The stocks below are ranked according to the number of hedge fund holders. Furthermore, these stocks have significant analyst coverage.
Note: Data extracted as of March 16, 2026.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10. Allogene Therapeutics, Inc. (NASDAQ:ALLO)
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the 10 most active penny stocks to buy.
On March 13, 2026, Biren Amin, an analyst at Piper Sandler, maintained an “Overweight” rating on Allogene Therapeutics, Inc. and increased the price target of the stock from $7 to $8.
Amin noted increased anticipation surrounding the company’s upcoming clinical catalyst. The interim analysis of the Phase 2 ALPHA3 study, which is assessing cemacabtagene ansegedleucel (cema-cel) as a first-line consolidation therapy for large B-cell lymphoma, remains the primary focus of investors, according to Amin. The data, which is anticipated to be released in April 2026, will evaluate the clearance of minimal residual disease (MRD). Piper believes that the setup is auspicious for cema-cel to achieve a 25%–30% MRD clearance advantage over observation.
The positive news follows Allogene Therapeutics, Inc.’s March 12, 2026, fourth-quarter and full-year 2025 update, which identified the ALPHA3 trial as a potential inflection point for its allogeneic CAR-T platform. The trial will recruit more than 60 locations worldwide and will evaluate whether early MRD-guided treatment can prevent lymphoma relapse.
Regarding the company’s financials, Allogene Therapeutics, Inc. reported a Q4 2025 net loss of $38.81 million, or $0.17 per share, and completed the year with $258.30 million in cash, extending its runway into Q1 2028. The company is also progressing programs such as ALLO-329 in autoimmune diseases.
Allogene Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to the development of off-the-shelf allogeneic CAR-T cell therapies for cancer and autoimmune diseases. The company’s goal is to provide a scalable, readily available cell therapy derived from healthy donors.
9. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 10 most active penny stocks to buy.
Analyst sentiment toward Iovance Biotherapeutics, Inc. remains constructive. With 73% of covering analysts retaining bullish ratings, the consensus price target of $9.50 suggests a potential upside of 135.15% as of March 16, 2026.
On March 11, 2026, at the Barclays 28th Annual Global Healthcare Conference, Iovance Biotherapeutics, Inc. presented its expansion strategy. The company outlined its ambitions to advance pipeline products in lung cancer and sarcoma while expanding the U.S. rollout of its melanoma drug, Amtagvi.
Iovance Biotherapeutics, Inc. reported a 50% gross margin in the fourth quarter and stated that Amtagvi could generate at least $1 billion in peak U.S. sales. As manufacturing moves in-house, further improvements are expected. The response rate in real-world data was 44%, which was higher than the 31% rate in its pivotal trial, and surpassed 50% when used earlier in treatment.
Iovance Biotherapeutics, Inc. also reported early progress in sarcoma, with three out of six patients responding in an initial study, a rate significantly higher than the historical response rate of less than 5%. Regulatory decisions for Amtagvi in the United Kingdom and Australia are anticipated in the first half of 2026, while a registrational trial is scheduled for the second quarter of 2026.
Iovance Biotherapeutics, Inc. is a biopharmaceutical company that specializes in developing tumor-infiltrating lymphocyte (TIL) cell therapies for cancer. One of its products, Amtagvi, is an autologous immunotherapy that uses patients’ immune cells to combat malignancies.
8. Bumble Inc. (NASDAQ:BMBL)
Bumble Inc. (NASDAQ:BMBL) is one of the 10 most active penny stocks to buy.
On March 12, 2026, Wall Street maintained a cautious outlook on Bumble Inc., balancing the company’s potential for profitability against its ongoing user and growth challenges.
Specifically, Wells Fargo maintained an “Equal Weight” rating and reduced the stock’s price target from $5.50 to $5.00. The investment firm emphasized that the company’s EBITDA in the fourth quarter and early in the first quarter was stronger than anticipated due to reduced marketing expenditures and alternative payment channels.
Nevertheless, Wells Fargo noted that Bumble Inc. is increasingly signaling that the development of new products and reinvestment in marketing are potential sources of revenue growth in 2027. However, by the latter half of 2026, investors will be closely watching the company for early traction.
Issuing a bearish outlook on the stock, Omar Dessouky, a Bank of America analyst, maintained an “Underperform” rating on Bumble Inc. and trimmed the firm’s price target from $3.50 to $3.30. The analyst acknowledged the evidence of early stabilization. However, he cautioned that 2026 will likely be a transition year as the company works to reverse declining payer trends and achieve sustainable growth.
Bumble Inc. is a global online dating platform that emphasizes women initiating the conversation. The Austin-based company, which was established in 2014, provides applications that are designed to facilitate connections in the areas of dating, companionship, and networking.
7. JetBlue Airways Corporation (NASDAQ:JBLU)
JetBlue Airways Corporation (NASDAQ:JBLU) is one of the 10 most active penny stocks to buy.
In response to rising fuel prices, analysts are reassessing their forecasts for JetBlue Airways Corporation despite comparatively stable travel demand.
On March 16, 2026, UBS analyst Atul Maheswari lowered the firm’s price target from $4 to $3.50. He attributed the rise in airline uncertainty to fuel price volatility. According to the analyst, first-quarter performance is likely to be in line with the midpoint of prior forecasts, with several carriers expected to preannounce results soon.
Despite the potential pressure on margins from the early-March increase in fuel costs, JetBlue Airways Corporation’s modest inventory exposure may lessen the impact on earnings. Meanwhile, revenue per available seat mile may continue to be supported by strong demand trends. Furthermore, UBS warned that due to continued uncertainty in fuel prices, some airlines may halt their full-year 2026 guidance.
In reaction to similar concerns, Evercore ISI analyst Duane Pfennigwerth lowered JetBlue Airways Corporation’s price target from $6 to $5 on March 12, 2026. This reflects updated forecasts across airline coverage to account for rising fuel costs, which were slightly offset by more robust revenue assumptions. Accordingly, the firm maintained an “In Line” rating.
JetBlue Airways Corporation is a U.S. airline that offers passenger transportation through brands such as JetBlue, JetBlue Vacations, Paisly, and TrueBlue. The company serves domestic, Caribbean, Latin American, Canadian, and transatlantic markets.
6. Enovix Corporation (NASDAQ:ENVX)
Enovix Corporation (NASDAQ:ENVX) is one of the 10 most active penny stocks to buy.
Analysts are optimistic about Enovix Corporation’s long-term battery technology potential, despite the risks associated with near-term commercialization.
According to Bank of America analyst Ruplu Bhattacharya, Enovix Corporation is leading the charge in next-generation high-energy-density lithium-ion batteries. He initiated coverage on March 12, 2026, with a “Neutral” rating and a $6 price target.
The analyst highlighted Enovix Corporation’s efforts to commercialize a 100% silicon-anode battery capable of providing greater energy capacity in smaller devices such as defense applications, smartphones, and smart eyewear.
However, Enovix Corporation warns that the potential is limited amid manufacturing difficulties, long qualification cycles for smartphones, and anticipated negative margins and cash flow in the coming years as the company continues to invest in growing production.
The broader sentiment on Wall Street is still positive despite these concerns.
A consensus price target of $12.50 suggests a potential upside of about 146.55%, with nearly 73% of analysts covering the stock maintaining bullish ratings on Enovix Corporation.
Enovix Corporation is a developer of silicon-anode lithium-ion batteries that utilize a proprietary 3D cell architecture to enhance energy density and cycle life. The company’s primary markets include consumer electronics, defense, electric vehicles, and energy storage.
5. Nuvation Bio Inc. (NYSE:NUVB)
Nuvation Bio Inc. (NYSE:NUVB) is one of the 10 most active penny stocks to buy.
As of March 16, 2026, Wall Street remains optimistic about Nuvation Bio Inc..
With over 90% of analysts covering Nuvation Bio Inc. maintaining bullish ratings, the consensus price target is $12.00, indicating a potential upside of 166.67%.
As investors focus on IBTROZI’s commercial launch and the company’s growing oncology pipeline, sentiment remains positive. Moreover, analyst confidence has been bolstered by Nuvation Bio Inc.’s early commercialization progress.
Copyright: wrangel / 123RF Stock Photo
Consequently, RBC Capital analysts increased the firm’s price target from $12.00 to $13.00 and reaffirmed their “Outperform” rating for Nuvation Bio Inc. on March 3, 2026. They highlighted the long-term potential across the company’s oncology pipeline and the strong physician adoption of IBTROZI.
According to Nuvation Bio Inc.’s (NYSE:NUVB) March 2, 2026, fourth-quarter earnings release, IBTROZI generated $15.70 million in net product revenue in Q4, with 216 new patients starting treatment. A $25.00 million milestone payment from Nippon Kayaku was the main driver of the company’s $26.20 million collaboration and license revenue, helping its cash and equivalents reach $529.20 million as of December 31, 2025. Nuvation Bio reported a net loss of $36.6 million, or $(0.11) per share. The net loss for the comparable period in 2024 was $49.4 million, or $0.15 per share.
Nuvation Bio Inc. is a biopharmaceutical company developing new treatments for difficult-to-treat cancers. The company was founded by David Hung in 2018, and its headquarters are in New York City.
4. Gossamer Bio, Inc. (NASDAQ:GOSS)
Gossamer Bio, Inc. (NASDAQ:GOSS) is included in our list of the 10 most active penny stocks to buy.
As of March 16, 2026, Gossamer Bio, Inc. has support from 44% of analysts who maintain a “Buy” rating for the stock. The consensus price target of $1.00 indicates an upside potential of 117.39%.
Amid an uncertain regulatory environment, analysts recently revised their forecasts for Gossamer Bio, Inc.’s primary therapy, seralutinib. This therapy is being developed for pulmonary arterial hypertension (PAH).
H.C. Wainwright & Co. maintained a “Buy” rating but lowered its price target for Gossamer Bio, Inc. from $10 to $5 on March 6, 2026. A more cautious outlook on the program’s development prospects led the firm to lower its probability of success for seralutinib in PAH from 70% to 50%.
Additionally, on March 5, 2026, Oppenheimer & Co. reiterated its “Outperform” rating while lowering its price target from $12 to $3. While citing short-term regulatory uncertainties, the firm pointed out that a June FDA interaction, Week 48 results, and future CT FRI substudy data might help reduce risk in seralutinib’s approval pathway and potentially lead to a re-rating in the shares.
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for immunology, inflammation, and oncology, notably GB001 for eosinophilic asthma. Established in 2015, it is based in San Diego, California.
3. UWM Holdings Corporation (NYSE:UWMC)
UWM Holdings Corporation (NYSE:UWMC) is one of the 10 most active penny stocks to buy.
As of March 16, 2026, Wall Street sentiment toward UWM Holdings Corporation remains divided. The consensus price target of $6 indicates an upside of 63.93%, with more than 65% of analysts covering the company maintaining a “Hold” rating. The stock has dropped more than 16% in 2026 so far.
On March 9, 2026, UWM Holdings Corporation revised its financial outlook in response to uncertainty in the mortgage market. With this revision, management aims to provide investors with a more thorough understanding of the company’s strategic direction and short-term performance.
Before Two Harbors Investment Corp.’s shareholder meeting on March 9, 2026, UWM Holdings Corporation updated its guidance. According to CEO Mat Ishbia, even if the proposed acquisition of Two Harbors fails to close, management projects total revenue of $800 million to $900 million in Q1 2026 and $3.5 billion to $4.5 billion in full-year 2026.
UWM Holdings Corporation’s loan origination volume in Q4 2025 reached $49.6 billion, its highest quarterly level since 2021, indicating strong operational momentum.
By 2026, UWM Holdings Corporation expects its AI voice assistant “Mia” to handle more than 12 million calls, improving efficiency and enabling the company to handle two to three times its current loan volume without adding more employees.
UWM Holdings Corporation is a wholesale mortgage lender that provides independent brokers and financial institutions with technology-driven tools for residential loan origination. It is headquartered in Pontiac, Michigan, and was established in 1986.
2. Peloton Interactive, Inc. (NASDAQ:PTON)
Peloton Interactive, Inc. (NASDAQ:PTON) is included in our list of the 10 most active penny stocks to buy.
On March 16, 2026, Peloton Interactive, Inc. made a strategic move away from its typical focus on at-home connected fitness, unveiling the Peloton Commercial Series, its first bike and treadmill designed for busy gym floors. The launch demonstrates Peloton’s broader goal of expanding across the global fitness and wellness ecosystem.
To address the multibillion-dollar commercial fitness market, Peloton Interactive, Inc.’s Commercial Business Unit (CBU) developed these products for the segment.
This unit was founded in 2025 by integrating Precor and Peloton for Business. According to CEO Peter Stern, the move represents Peloton’s entry into the gym industry. He noted that the company aims to close the fitness gap between home and gym by combining its digital platform and training programs with robust commercial-grade equipment.
Peloton Interactive, Inc.’s software ecosystem and Precor’s industrial-grade architecture will be combined to create the first connected bike and treadmill in the Commercial Series. The CBU recorded 10% year-over-year revenue growth in fiscal Q2, and Peloton may expand internationally due to Precor’s presence in more than 60 countries.
Shipments to the United States, United Kingdom, Canada, Germany, Australia, and Austria are anticipated in late 2026, and the products will make their debut at the Health & Fitness Association Show.
Peloton Interactive, Inc. offers streaming instructor-led exercise classes and connected fitness equipment through product sales and subscriptions. The company was established in 2012 and is headquartered in New York City.
1. Snap Inc. (NYSE:SNAP)
Snap Inc. (NYSE:SNAP) is included in our list of 10 most active penny stocks to buy.
On March 13, 2026, Snap Inc. shares fell to a 52-week low of $4.52. This reflects growing investor concerns about the company as it navigates a challenging market environment.
The stock has declined by more than 46.35% in the last year and 42.57% year-to-date, suggesting that advertising demand remains weak.
Despite these challenges, analysts remain cautious about Snap Inc.’s (NYSE:SNAP) potential.
Brian Nowak, an analyst at Morgan Stanley, lowered his price target for Snap Inc. from $9.50 to $6.50 on February 23, 2026. He kept the stock’s “Equal Weight” rating.
The analyst noted that Snap Inc.’s primary business is performing better than expected. He also emphasized the need for clarity regarding when the company will make about $400 million in high-margin income from its deal with Perplexity, which remains in the negotiation stage.
Furthermore, Morgan Stanley noted that Snap Inc.’s performance remains below that of the broader digital advertising industry.
Separately, Citigroup reduced its price target for Snap Inc. from $10 to $6 in mid-February 2026, while maintaining a “Neutral” rating in response to the company’s Q4 results. The target adjustment was driven by ongoing headwinds in brand advertising.
Snap Inc., a technology company founded in 2010 by Evan Spiegel and Robert C. Murphy, operates Snapchat, a visual messaging platform headquartered in Santa Monica, California.
